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ABSTRACT: A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogues of
biologically active molecules will be discussed. A comparison of the inhibitory activity of these compounds to the known
type-2 diabetes compound (sitagliptin) against dipeptidyl peptidase-4 (DPP-4) will be shown.
Diabetes remains one of the world’s largest health
problems with numerous different factors contributing to
its pathogenesis. According to the WHO in 2013
1, 347 million people were diagnosed with type-2 diabetes
mellitus, with an alarming growth predicted over the next
decade.
Type-2 diabetes is a chronic disease, characterized by ele-
vated blood sugar levels, leading to severe vascular com-
plications and an increased mortality risk. Dipeptidyl pep-
tidase-4 (DPP-4), a widely distributed serine protease
found solubilized in blood or anchored into tissue mem-
branes, is involved in glucose metabolism and is now a
validated target for anti-diabetic therapy. Inhibition of
DPP-4 has been shown to result in indirect stimulation of
insulin secretion.2-3 The mechanism of inhibition4-5 is
through an increase in the release of incretin (GLP-1 and
GIP) following food intake, therefore inhibiting glucagon
release, which in turn increases insulin secretion and de-
creases blood glucose levels.6
Sitagliptin (JanuviaTM) was the first approved DPP-4 in-
hibitor launched by Merck in 2006.7 It was followed by
several, structurally diverse DPP-4 inhibitors namely
vildagliptin, saxagliptin, alogliptin, linagliptin and Gemi-
gliptin and recent communications highlighting further
compounds such as omarigliptin8 and imigliptin9 have
been recently communicated (Figure 1).
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Figure 1. Approved DPP-4 inhibitors: sitagliptin, vildagliptin,
saxagliptin, alogliptin, linagliptin and the clinical candidates
imigliptin and omarigliptin,
The so called “gliptins” are under investigation for other
potential therapeutic uses. For example, it was reported
that potential substrates of DPP-4 could have implica-
tions in other metabolic disorders and that DPP-4 inhibi-
tors could be utilised in the treatment of diseases associ-
ated with the immune/inflammatory response, heart fail-
ure, cancer and neurodegenerative disorders. In addition
it was stated that a positive role of DPP-4 inhibition was
observed in diseases of the kidney and the cardiovascular
system.10
In our on-going exploration of novel constrained
molecular scaffolds containing substituted ring-fused
1,2,4-triazoles, we were drawn to the possibility of
substituting the piperazine-fused 1,2,4-triazolo group
present in sitagliptin with a new tricyclic octahydro-
[1,2,4]triazolo[4,3-a][1,6]naphthyridine molecular scaffold
(1a-b) to generate sitagliptin hybrid structures of the type
shown in compounds 2a and 2b (Figure 2).
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Figure 2. Novel tricyclic scaffold 1a-b and proposed DPP-4
inhibitors 2a and 2b. Compounds 2a and 2b would exist as a
1:1 mixture of either cis- or trans-diastereoisomers.
To test our hypothesis, preliminary docking studies
were carried out with the known crystal structure of
sitagliptin in DPP-4 (pdb code 1X70).11-12 The cis-fused
diastereomer 2a (R2 = CF3) showed a good overlay with
sitagliptin as well as a good topographical fit into the
enzyme pocket when compared to the trans-fused
disatereomer 2b. As expected, the 2, 4, 5-trifluorophenyl
group fully occupied the S1 pocket, which was previously
reported by the Merck group.13 From the docking studies
it was noted that the key interactions observed in
sitagliptin; namely the four hydrogen bond interactions
with Tyr662, Glu205 and Glu206 resulting from the (R)-
amino group were still preserved along with the water
molecule bridge present between the amide carbonyl of
2a with Tyr547. Phe357 provides a ߨെ ߨ interaction with
the triazole core of compound 2a. However, it was
noticed that the inclusion of the sterically demanding
tricyclic portion of 2a led to a change in the orientation of
the CF3 group, losing the known interaction of this moiety
in sitagliptin with Arg358 and Ser209. However, we felt
that this potential loss in activity would be compensated
by allowing us the exciting potential for discovering new
interactions within the DPP-4 protease backbone (Figure
3).
Figure 3. Compound 2a (blue) docked into the DPP-4 active
site (pdb code 1X70) overlaid with sitagliptin (magenta).
Only one of the two possible diastereoisomers of 2a with the
optimal docking pose is shown. The image was generated
using PyMol.
The novel scaffold 1 (represented as examples 9a and
9b) was synthesized in a robust six step racemic sequence
starting from commercially available ethyl 4-
oxopiperidine-1-carboxylate 3. The first step in the
sequence was the enamine alkylation with ethyl acrylate
under Dean Stark conditions that resulted in a high yield
of the -keto ester 4.14 Conversion of 4 into the O-methyl
oxime 5 using methoxyamine hydrochloride in pyridine,
delivered the desired compound in a 1:1.5 mixture of
imine isomers. These were converted to the bicyclic
lactam 6 using Raney Nickel in 7N ammonia in methanol
under an atmosphere of hydrogen. At this stage the
isomers generated in the ring closure were separated by
flash chromatography on silica gel. Unfortunately, no
assignment of the ring geometry was possible for the two
separated lactam diastereoisomers (7a and 7b) from NMR
spectroscopy. Therefore single crystal X-ray
crystallography was needed to determine the relative
configuration of the two isomers.15 Each of the isomers
(7a and 7b) was converted into their corresponding
thiolactams (8a and 8b) using Lawessons’ reagent.16-17
These thiolactams were converted into the corresponding
tricyclic triazoles (9a and 9b) by refluxing in toluene with
2,2,2-trifluoroacetohydrazide (Scheme 1).
Scheme 1. Synthetic route to compounds 9a and 9ba.
aReagents and conditions: a) 1. Pyrrolidine, benzene, rf, Dean
Stark; 2. Ethyl acrylate, benzene, rf, o.n., 3. water, 2h, rf,
69% (2 steps); b) MeONH2
.HCl, pyridine, 84%; c) Raney-
Nickel, 7N ammonia in MeOH, H2, o.n., 86%; d) flash
chromatography ethyl acetate/hexane/methanol (10:1:1), ratio
1:4; e) Lawessons’ reagent, toluene, rf, o.n., 90-94%. f) CF3-
hydrazide, toluene, 1-3d, 120oC, 40-84%. Compounds 9a and
9b exists as a 1:1 mixture of enantiomers.
The molecular scaffolds (9a and 9b) were inserted in
the sitagliptin structural motif by deprotection of the
carbamates (9a and 9b) in ethanol/water using potassium
hydroxide under refluxing conditions to afford the key
molecular scaffolds (Scheme 1: 1a and 1b, R1 = H, R2 = CF3)
ready for reaction with the commercially available acids
10 and 11. This coupling was high yielding and the final
deprotection to the HCl salts (2a-b and 12a-b) was carried
out with 4N HCl in dioxane (Scheme 2).
Scheme 2. Synthetic route to compounds 2a-b and
12a-ba.
aReagents and conditions: a) 1) KOH, water/ethanol, rf, o.n.,
2) 10 or 11 + EDCI, HOBt, DMF, rt, o.n., 77-91%, b) 4N HCl in
dioxane. Compounds 2a-b and 12a-b exist as a 1:1 mixture of
either cis- or trans- diastereoisomers.
As the synthesis of the scaffolds 9a and 9b was in race-
mic form, the separation of the diastereoisomers of com-
pounds 2a and 2b was required. Rewardingly, both dia-
stereomers proved separable under chiral HPLC condi-
tions with purity of at least 99% de. Therefore 2a was sep-
arated into the single diastereomers (13 and 14) and 2b
was separated as single diasteromers (15 and 16). Due to
the robust nature of the synthetic procedure, a small se-
ries of further analogues was also produced (examples 17,
18, 19 and 20, see supplementary information for the syn-
thesis and yields). Inhibitory activity against DPP-4 was
then determined (Table 1).18
Table 1. DPP-4 inhibitory activity
Compound cis- or
trans-
R3 R2 DPP-4
IC50[nM] a
12a cis- H CF3 695±31b
12b trans- H CF3 2801±86b
13 cis- F CF3 28±1c
14 cis- F CF3 70±2c
15 trans- F CF3 145±5c
16 trans- F CF3 537±23c
17 cis- F Ethyl 85±3b
18 trans- F Ethyl 108±6b
19 cis- F CF2CF3 67±2b
20 trans- F CF2CF3 258±11b
aSitagliptin IC50 22±2 nM (n=20); b1:1 mixture of diastere-
omers; csingle diastereomer with unknown absolute configu-
ration.
Gratifyingly, the compounds demonstrated very good
levels of DPP-4 activity when compared to sitagliptin
(IC50 22±2 nM). Notably, in all the tested analogues the
cis-isomer reproducibly showed a better level of biological
activity when compared to the trans-isomer (for example
compare 12a and 12b and 17 and 18). As this is an observa-
tion throughout all the synthesized derivatives it demon-
strates the effect of the connection of the rings to be im-
portant to allow the cis-fused compounds to establish
optimal interactions within the active site of DPP-4. It
was also encouraging to see that the separated diastereoi-
somers of 2a and 2b were shown to have either a 2.5-fold
(cis-isomers, compare compounds 13 and 14) or 3.6-fold
(trans-isomers compare compounds 15 and 16) difference
in activity, demonstrating further molecular recognition
for either the novel cis-fused or trans-fused tricyclic scaf-
folds within the DPP-4 active site. This was in agreement
with our original docking studies (see figure S1 supple-
mentary material) where the 2a cis-isomers (13-14) were
observed to have a better topographical fit into the DPP-4
active site, preserving the water molecule bridge present
between the amide carbonyl of 2a with Tyr547. However,
from the docking work the 2b trans-isomers (15-16) were
shown to lack this key interaction and, as a consequence,
we proposed they would possess lower DPP-4 inhibitory
activity.
The enlargement of the CF3 group in 2a to both the
ethyl-substituted analogue 17 and the CF2CF3-substituted
analogue 19 led to a decrease in inhibitory activity. The
lack of the three fluorine atoms in the aromatic region
(12a and 12b) substantially decreased the activity, which
concurred with similar observations previously reported
by the Merck group.
In order to show the influence of the rigid tricyclic ring
system towards DPP-4 inhibitory activity, the bicyclic
compound 24 was synthesized. The commercially availa-
ble amine 21 was converted to the substituted 1,2,4 tria-
zole 23 in 15% yield.19 Final deprotection of the carbamate
group in 23 was carried out under established standard
conditions using KOH in water/ethanol and the coupling
to the final bicyclic compound 24 was achieved using acid
11, followed by deprotection using 4N HCl in dioxane
(Scheme 3).
Scheme 3. Synthesis of the open chain compound 24a.
aReagents and conditions: a) Ac2O, CH2Cl2, NEt3, rt, o.n.
84%; b) 1) POCl3, CHCl3, pyridine, 2) CF3CONHNH2, CHCl3,
3) 2M HCl, 15% (3 steps); c) 1) KOH, water/EtOH, 2) 11, EDCI,
HOBt, DMF, rt, o.n., 93%, d) 4N HCl in dioxane.
In order to gain insight into the impact of ring size for
DPP-4 inhibitory activity, the synthesis of the novel cis-
fused hexahydro-6H-[1,2,4]triazolo[4',3':1,5]pyrrolo[3,2-
c]pyridine analogue 31 was carried out. The synthesis to
the 5-membered lactams (28 and 29) followed a slightly
different approach than for the 6, 6-membered lactams
7a-b. Commercially available ethyl 4-oxopiperidine-1-
carboxylate 3 was converted into tert-butylester 25 using
LDA and tert-butyl 2-bromoacetate. The tert-butylester 25
was converted through to the substituted benzylamine 26
via a reductive amination reaction using benzylamine and
sodium triacetoxyborohydride in 1,2-dichloroethane.
Compound 26 was trans-esterified with 0.6M HCl in
methanol to yield the methyl ester 27, which was catalyti-
cally-hydrogenated using Pd/C in MeOH under an at-
mosphere of hydrogen. The final ring closure to the key
bicyclic lactams 28 and 29 was carried out with potassium
carbonate in methanol and the diastereomers were sepa-
rated by flash column chromatography. Once more struc-
tural determination of the separated diastereomers (28
1nd 29) was performed through X-ray crystallography [see
reference 15] (Scheme 4).
Scheme 4. Synthesis of the 6,5-bicyclic intermediates
28 and 29.
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The separated cis-fused isomer 29 was converted
through to the final product through the standard syn-
thetic procedure (Scheme 5).
Scheme 5. Synthesis of the 6,5,5-tricyclic compound
33a.
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o.n., 66%, b) CF3-hydrazide, toluene, 1-3d, rf, 70%, c) KOH,
water/ethanol, rf, o.n., 50 %, d) 11 + EDCI, HOBt, DMF, rt,
o.n., 37%, e) 4N HCl in dioxane. Compound 31 exists as a 1:1
mixture of cis-diastereoisomers.
The DPP-4 inhibitory activity for compounds 24 (IC50
100±4 nM) and 31 (IC50 94±4 nM) was established show-
ing a reduced level of activity compared to 13 (separated
most active isomer of compound 2a, IC50 28±1 nM). In
order to understand the DPP-4 inhibitory activity of com-
pounds 2a, 24 and 31, the compounds were energy mini-
mized and docked into the known crystal structure of
sitagliptin in DPP-4. As previously mentioned, compound
2a displayed a good topographical fit into the enzyme
pocket, whereas compound 31 docked to allow overlay of
the trifluoromethyl group of 31 with that of sitagliptin.
However, in achieving this topographical fit, the Phe357
π-π interaction with the triazole core of compound 31 is
lost due to a steric clash imposed by the rigid tricyclic
ring system and this could be an explanation for the ob-
served loss in DPP-4 inhibitory potency of 31 when com-
pared to 2a. For the bicyclic compound 24, once more
there is a good topographical fit into the enzyme pocket,
however the Phe357 π-π interaction with the triazole core 
of compound 24 is not present and this could again be an
explanation for the observed loss in DPP-4 inhibitory po-
tency (Figure 4).
Figure 4. Compounds 2a, 24 and 31 (blue) docked into the DPP-4 active site (pdb code 1X70) shown overlaid with sitagliptin
(magenta). For compounds 2a and 31 only the single enantiomer with the optimal docking pose is shown. The image was gener-
ated using PyMol.
In summary, we have shown the successful synthesis of
promising new inhibitors for DPP-4 along with prelimi-
nary docking studies of the active compounds into the
active site of the protease. The compounds demonstrated
a range of activities with compound 13 (unknown abso-
lute conformation) possessing similar levels of DPP-4
inhibitory activity to that of sitagliptin. We have shown
the stereochemical preference for the cis- diastereomer of
the novel octahydro-[1,2,4]triazolo[4,3-
a][1,6]naphthyridine tricyclic ring system and we are cur-
rently investigating a chiral synthesis of the key interme-
diates along with further structure design-based synthesis
of analogues to interrogate the SAR within this interest-
ing new tricyclic scaffold which we will report in due
course.
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